Marina Gets Institutional Approval to Begin Phase I Study of FAP Drug
November 04, 2010
Marina Gets Institutional Approval to Begin Phase I Study of FAP Drug
"Clinical site approval at MGH marks the last regulatory requirement prior to moving our first drug candidate into human trials," Michael French, president and CEO of Marina, said in a statement.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Marina Biotech Advances FAP Drug into Phase I
March 17, 2011 / Gene Silencing News - Marina Preps for Additional Patient Enrollment in FAP Trial, Predicts Pharma Partnership This Year
January 26, 2012 / Gene Silencing News - Calando, Others Miss 2010 Partnering Guidance as Industry Takes Sober View of RNAi
January 6, 2011 / Gene Silencing News - Marina Receives Orphan Drug Designation for FAP Drug, Notice of Allowance for Delivery Patent Application
January 6, 2011 / Gene Silencing News - Marina Pipeline on Track with FAP Trial in 2010, But Could Miss Partnership Guidance
November 18, 2010 / Gene Silencing News